Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 18, 2026Biological ResearchOpen Access

The progress and challenges of mesenchymal stromal cell-based therapy for diabetes and its complications

View Full Paper
Ask AI
Bookmark
Share

Authors

LTLeyi TuTGTianyun GaoPSPingping Shen

Discussion

Loading...

Member takes

Overview

Comprehensive review highlights MSC therapy's efficacy in diabetes and its complications, suggesting improvements needed for long-term impact.

Key Points

  • This review aims to analyze the potential of mesenchymal stromal cell therapy in the treatment of diabetes and its complications.
  • Systematic comparison of MSC tissue sources including umbilical cord, bone marrow, and Wharton's jelly.
  • Analysis of MSC engineering techniques to improve therapeutic outcomes.
  • Synthesis of delivery protocols for diabetic complications like wounds, nephropathy, retinopathy, neuropathy, and cardiomyopathy.
  • Incorporation of recent clinical trial data (2020–2023) and preclinical studies.
  • MSC therapy shows significant safety and efficacy in treating diabetes-related complications.
  • Therapeutic efficacy declines by 40–60% after six months in most trials.
  • Limited cell engraftment and compromised function are primary factors affecting long-term results.

Cite This Study

Tu et al. (2026) studied this question.

synapsesocial.com/papers/69ba422e4e9516ffd37a22dahttps://doi.org/10.1186/s40659-026-00687-w
View Full Paper
Ask AI
Bookmark
Share